HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Guest Access | Sign In via User Name/Password

This Article Full Text Free Full Text (PDF) Free Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Johnson, D. H. Search for Related Content PubMed PubMed Citation Articles by Johnson, D. H.

Management of Small Cell Lung Cancer^*

Current State of the Art

^* From the Division of Medical Oncology, Vanderbilt University Medical School, Nashville, TN.

Correspondence to: David H. Johnson, MD, Professor of Medicine and Director, Division of Medical Oncology, Vanderbilt University Medical School, Nashville, TN 37232-5536; e-mail: david.johnson{at}mcmail.vanderbilt.edu

Small cell lung cancer (SCLC) is a common malignancy that is rapidly fatal if left untreated, with most patients surviving < 6 months. Currently, patients with SCLC are treated with chemotherapy with or without thoracic radiotherapy. Randomized trials have demonstrated the superiority of multiagent regimens over single-agent therapies, with the combination of cisplatin and etoposide being the initial regimen of choice for most patients, regardless of stage at presentation. Dose escalation, weekly chemotherapy, alternating noncross-resistant chemotherapy, and maintenance chemotherapy have been evaluated in SCLC, with no convincing data to date demonstrating an advantage for these strategies over conventional treatment strategies. Second-line therapy may be effective in selected patients, depending on the interval between primary treatment and recurrence, response to primary therapy, and the agents used for initial treatment. Radiotherapy is generally accepted as an essential component of optimal management of limited-stage disease, although sequencing, timing, fractionation, dose, and field size remain less than adequately defined. Finally, the routine use of prophylactic cranial irradiation remains controversial, and currently should be reserved for patients in complete remission.

This article has been cited by other articles:

				E. M. Kamel, D. Zwahlen, M. T. Wyss, K. D. Stumpe, G. K. von Schulthess, and H. C. Steinert Whole-Body 18F-FDG PET Improves the Management of Patients with Small Cell Lung Cancer J. Nucl. Med., December 1, 2003; 44(12): 1911 - 1917. [Abstract] [Full Text] [PDF]

				J. Laskin, A. Sandler, and D. H. Johnson An Advance in Small-Cell Lung Cancer Treatment--More or Less J Natl Cancer Inst, August 6, 2003; 95(15): 1099 - 1101. [Full Text] [PDF]

				C. Lu, R. Komaki, J. S. Lee, D. M. Shin, J. L. Palmer, B. J. Coldman, K. M. Pisters, J. M. Kurie, F. V. Fossella, and B. S. Glisson A Phase I Study of Topotecan/Paclitaxel Alternating with Etoposide/Cisplatin and Thoracic Irradiation in Patients with Limited Small Cell Lung Cancer Clin. Cancer Res., June 1, 2003; 9(6): 2085 - 2091. [Abstract] [Full Text] [PDF]

				G. A. Masters, L. Declerck, C. Blanke, A. Sandler, R. DeVore, K. Miller, and D. Johnson Phase II Trial of Gemcitabine in Refractory or Relapsed Small-Cell Lung Cancer: Eastern Cooperative Oncology Group Trial 1597 J. Clin. Oncol., April 15, 2003; 21(8): 1550 - 1555. [Abstract] [Full Text] [PDF]

				D. H. Johnson "The Guard Dies, It Does Not Surrender!" Progress in the Management of Small-Cell Lung Cancer? J. Clin. Oncol., December 15, 2002; 20(24): 4618 - 4620. [Full Text] [PDF]

				S. Sundstrom, R. M. Bremnes, S. Kaasa, U. Aasebo, R. Hatlevoll, R. Dahle, N. Boye, M. Wang, T. Vigander, J. Vilsvik, et al. Cisplatin and Etoposide Regimen Is Superior to Cyclophosphamide, Epirubicin, and Vincristine Regimen in Small-Cell Lung Cancer: Results From a Randomized Phase III Trial With 5 Years' Follow-Up J. Clin. Oncol., December 15, 2002; 20(24): 4665 - 4672. [Abstract] [Full Text] [PDF]

				H. A. Nabi and J. M. Zubeldia Clinical Applications of 18F-FDG in Oncology J. Nucl. Med. Technol., March 1, 2002; 30(1): 3 - 9. [Abstract] [Full Text] [PDF]

				R. M. Bremnes, S. Sundstrom, J. Vilsvik, and U. Aasebo Multicenter Phase II Trial of Paclitaxel, Cisplatin, and Etoposide With Concurrent Radiation for Limited-Stage Small-Cell Lung Cancer J. Clin. Oncol., August 1, 2001; 19(15): 3532 - 3538. [Abstract] [Full Text] [PDF]